|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer:a randomized phase Ⅲ ARTIST trial显示文摘The efficacy and safety of bevacizumab with modified irinotecan,leucovorin bolus,and 5-fluorouracil intravenous infusion(mIFL) in the first-line treatment of metastatic colorectal cancer(mCRC) has not been well evaluated in randomized clinical trials in Chinese patients.We conducted a phrase Ⅲ trial in which patients with previously untreated mCRC were randomized 2:1 to the mIFL [irinotecan(125 mg/m2),leucovorin(20 mg/m2) bolus,and 5-fluorouracil intravenous infusion(500 mg/m2) weekly for four weeks every six weeks] plus bevacizumab(5 mg/kg every two weeks) group and the mIFL group,respectively.Co-primary objectives were progression-free survival(PFS) and 6-month PFS rate.In total,214 patients were enrolled.Our results showed that addition of bevacizumab to mIFL significantly improved median PFS(4.2 months in the mIFL group vs.8.3 months in the bevacizumab plus mIFL group,P < 0.001),6-month PFS rate(25.0% vs.62.6%,P < 0.001),median overall survival(13.4 months vs.18.7 months,P = 0.014),and response rate(17% vs.35%,P = 0.013).Grades 3 and 4 adverse events included diarrhea(21% in the mIFL group and 26% in the bevacizumab plus mIFL group) and neutropenia(19% in the mIFL group and 33% in the bevacizumab plus mIFL group).No wound-healing complications or congestive heart failure occurred.Our results suggested that bevacizumab plus mIFL is effective and well tolerated as first-line treatment for Chinese patients with mCRC.Clinical benefit and safety profiles were consistent with those observed in pivotal phase Ⅲ trials with mainly Caucasian patients. | Zhong-Zhen Guan Jian-Ming Xu Rong-Cheng Luo Feng-Yi Feng Li-Wei Wang Lin Shen Shi-Ying Yu Yi Ba Jun Liang Dong Wang Shu-Kui Qin Jie-Jun Wang Jing He Chuan Qi Rui-Hua Xu | 2011 | Chinese Journal of Cancer2011，30，10： | 48 |
| 2 | Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third-or further-line treatment显示文摘Objective:Anlotinib hydrochloride is a multitarget tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor,fibroblast growth factor receptor,platelet-derived growth factor receptor,c-Kit,and c-MET;therefore,it exhibits both antitumor and anti-angiogenetic activities.A phase III trial has shown that anlotinib improved progression-free survival(PFS)and overall survival(OS)in patients with advanced non-small cell lung cancer(NSCLC),who presented with progressive disease or intolerance after standard chemotherapy.This study aimed to analyze the characteristics of patients receiving anlotinib treatment to determine the dominant populations who are fit for the treatment.Methods:Data were collected from March 2015 to January 2017 from a randomized,double-blind,placebo-controlled,multicenter,phase III trial of anlotinib(ALTER0303).A total of 437 patients were enrolled and randomly allocated(2:1)to the anlotinib and placebo groups.Kaplan–Meier analysis and log-rank test were performed to compare PFS and OS.Cox proportional hazards model was adopted for multivariate prognostic analysis.Results:Multivariate analysis indicated that high post-therapeutic peripheral blood granulocyte/lymphocyte ratio and elevated alkaline phosphatase levels were independent risk factors for PFS.Meanwhile,elevated thyroid-stimulating hormone,blood glucose,and triglyceride levels;hypertension;and hand–foot syndrome were independent protective factors of PFS.High posttherapeutic peripheral blood granulocyte/lymphocyte ratio,an Eastern Cooperative Oncology Group(ECOG)score≥2,and the sum of the maximal target lesion length at baseline were independent risk factors of OS,and hypertriglyceridemia was an independent protective factor of OS.Conclusions:This study preliminarily explored the possible factors that affected PFS and OS after anlotinib treatment in patients with advanced refractory NSCLC,and the baseline characteristics of the therapeutically dominant populations were then identified. | Jing Wang Yizhuo Zhao Qiming Wang Li Zhang Jianhua Shi Zhehai Wang Ying Cheng Jianxing He Yuankai Shi Hao Yu Yang Zhao Weiqiang Chen Yi Luo Xiuwen Wang Kejun Nan Faguang Jin Jian Dong Baolan Li Zhujun Liu Baohui Han Kai Li | 2018 | Cancer Biology & Medicine2018，15，4： | 46 |
| 3 | Polymorphisms in PPARD,PPARG and APM1 associated with four types of Traditional Chinese Medicine constitutions显示文摘Based on the theory of constitution of Traditional Chinese Medicine (TCM), the human population is divided into nine constitutions including one balanced constitution (Normality) and eight unbalanced constitutions (Yang-deficiency, Yin-deficiency, Phlegm-wetness, Qi-deficiency, Wetness-heat, Blood stasis, Depressed constitution, and Inherited special constitution). Different constitutions have specific metabolic features and different susceptibility to certain diseases. However, whether a genetic basis accounts for such constitution classifica-tion is yet to be determined. Here we performed a genetic study to assess the association between genetic variations of metabolic genes in-cluding PPARD, PPARG and APM1 and the constitutions. A total of 233 individuals of the Han population in China were classified into four groups, Normality, Yang-deficiency, Yin-deficiency and Phlegm-wetness with whom 23 single nucleotide polymorphisms (SNPs) in the three genes were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Biased distri-bution of PPARD rs2267669 and rs2076167, APM1 rs7627128 and rs1063539 in Yang-deficiency, PPARG Pro12Ala in Yin-deficiency and PPARD rs2076167, APM1 rs266729 and rs7627128 in Phlegm-wetness were observed. The frequencies of Haplotype13 (Hap13) of PPARG in Yin-deficiency, Hap25 of APM1 in Yang-deficiency and Hap2 of PPARD and Hap14 of PPARG in Phlegm-wetness, were significantly different from those in Normality, suggesting those might be group-associated haplotypes. These results suggested that single SNP and hap-lotypes of PPARD, PPARG and APM1 may underlie the genetic basis of the constitutions classified in TCM. | Yanrui Wu Yina Cun Jing Dong Jingru Shao Shengjun Luo Shengjie Nie Haijing Yu Bingrong Zheng Qi Wang Chunjie Xiao | 2010 | Journal of Genetics and Genomics2010，37，6： | 36 |
| 4 | A 4-bp Insertion at ZmPLA 1 Encoding a Putative Phospholipase A Generates Haploid Induction in Maize显示文摘 | Chenxu Liu Xiang Li Dexuan Meng Yu Zhong Chen Chen Xin Dong Xiaowei Xu Baojian Chen Wei Li Liang Li Xiaolong Tian Haiming Zhao Weibin Song Haishan Luo Qinghua Zhang Jinsheng Lai Weiwei Jin Jianbing Yan Shaojiang Chen | 2017 | Molecular Plant2017，10，3： | 39 |
| 5 | Recent progress in medium-Mn steels made with new designing strategies, a review显示文摘After summarizing the relevant researches on the medium Mn steels in references, two new targets on the tensile properties have been defined. One is that both transformation-induced(TRIP) and twinninginduced plasticity(TWIP) could be realized for the steel with a relatively low Mn content, which exhibits the similar tensile properties to the classical TWIP steels with higher Mn content. The other is to achieve ultrahigh ultimate tensile strength(>1.5 GPa) without sacrificing formability. To achieve these goals,new designing strategies was put forward for compositions and the processing route. In particular, warm rolling was employed instead of the usual hot/cold rolling process because the former can produce a mixture of retained austenite grains with different morphologies and sizes via the partial recrystallization. Consequently, the retained austenite grains have a wide range of mechanic stability so that they can transform to martensite gradually during deformation, leading to enhanced TRIP effect and then improved mechanic properties. Finally, it is succeeded in manufacturing these targeted medium Mn steels in laboratory, some of them even exhibit better tensile properties than our expectation. | Bin Hu Haiwen Luo Feng Yang Han Dong | 2017 | Journal of Materials Science & Technology2017，33，12： | 31 |
| 6 | 5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers显示文摘象 5-methylcytosine (5mC ) 和 5-hydroxymethylcytosine (5hmC ) 那样的 DNA 修正是知道在哺乳动物影响全球基因表示的 epigenetic 标记。在人的染色体,与基因表示的靠近的关联和高化学的稳定性给他们的流行,这些 DNA epigenetic 标记能为癌症用作理想的 biomarkers 诊断。利用一种高度敏感、选择的化学标记技术,我们这里报导在传播没有房间的 DNA ( cfDNA )并且在从最近与 colorectal 诊断的 260 个病人的一个队收集的配对的肿瘤和邻近的纸巾的 genomic DNA ( gDNA )的 5hmC 的染色体宽的介绍,胃,胰腺,从 90 个健康个人的肝或甲状腺癌症和正常纸巾。5hmC 主要在与开的染色质和容许的 histone 修正重合的 transcriptionally 活跃的区域被散布。柔韧的联系癌症的 5hmC 签名在 cfDNA 被识别为特定的癌症类型是特征的。传播 cfDNA 的 5hmC 底 biomarkers colorectal 和胃的癌症是高度预兆的并且比常规 biomarkers 优异并且比得上从织物活体检视的 5hmC biomarkers。因此,这新策略能从血样品的分析为癌症的诊断和预后导致有效、最低限度地侵略的方法的发展。 | Wenshuai Li Xu Zhang Xingyu Lu Lei You Yanqun Song Zhongguang Luo Jun Zhang Ji Nie Wanwei Zheng Diannan Xu Yaping Wang Yuanqiang Dong Shulin Yu Jun Hong Jianping Shi Hankun Hao Fen Luo Luchun Hua Peng Wang Xiaoping Qian Fang Yuan Lianhuan Wei Ming Cui Taiping Zhang Quan Liao Menghua Dai Ziwen Liu Ge Chen Katherine Meckel Sarbani Adhikari Guifang Jia Marc B Bissonnette Xinxiang Zhang Yupei Zhao Wei Zhang Chuan He Jie Liu | 2017 | Cell Research2017，27，10： | 30 |
| 7 | Chinese Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia and Related Diseases显示文摘 | Zou, He-Jian Wu, Hu-Sheng Zhou, Jing-Guo Zeng, Xue-Jun Dai, Lie Wu, Hua-Xiang Zhu, Xiao-Xia Mei, Chang-Lin Hao, Chuan-Ming Chen, Nan Liu, Bi-Cheng Chen, Jiang-Hua Yang, Li Nie, Jing Yu, Chen Peng, Ai Yu, Sheng-Qiang Li, Lin Ge, Jun-Bo Huo, Yong Zhang, Shu-Yang Chen, Yun-Dai Dong, Yu-Gang Liang, Chun Dai, Yu-Xiang Gao, Xin Li, Chang-Gui Zhao, Jia-Jun Chen, Hai-Bing Cheng, Zhi-Feng Lin, Huan-Dong Guan, Yang-Tai Wang, Kai Luo, Ben-Yan Dai, Ruo-Lian Jiang, Quan Xue, Luan Liang, Chao-Chao Chen, Ming Fan, Song | 2017 | Chinese Medical Journal2017，，20： | 30 |
| 8 | Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing,locally advanced or metastatic gastric or gastroesophageal junction cancer:a single-arm phase II study显示文摘Background:Current treatment options for human epidermal growth factor receptor 2(HER2)-overexpressing gastric cancer at third-line have shown limited clinical benefit.Further,there is no specific treatment for HER2 immunohistochemistry(IHC)2+and fluorescence in-situ hybridization-negative patients.Here,we report the efficacy and safety of a novel anti-HER2 antibody RC48 for patients with HER2-overexpressing,advanced gastric or gastroesophageal junction cancer.Methods:Patients with HER2-overexpressing(IHC 2+or 3+),locally advanced or metastatic gastric or gastroesophageal junction cancer who were under at least second-line therapy were eligible and received RC482.5 mg/kg alone every 2 weeks.The primary endpoint was the objective response rate(ORR)assessed by an independent review committee.Secondary endpoints included progressionfree survival(PFS),overall survival(OS),duration of response,time to progression,disease control rate,and safety.Results:Of 179 patients screened,125 were eligible and received RC48 treatment.The ORR was 24.8%(95%confidence interval[CI]:17.5%-33.3%).The median PFS and OS were 4.1 months(95%CI:3.7-4.9 months)and 7.9 months(95%CI:6.7-9.9 months),respectively.The most frequently reported adverse events were decreased white blood cell count(53.6%),asthenia(53.6%),hair loss(53.6%),decreased neutrophil count(52.0%),anemia(49.6%),and increased aspartate aminotransferase level(43.2%).Serious adverse events(SAEs)occurred in 45(36.0%)patients,and RC48-related SAEs were mainly decreased neutrophil count(3.2%).Seven patients had adverse events that led to death were not RC48-related.Conclusions:RC48 showed promising activity with manageable safety,suggesting potential application in patients with HER2-overexpressing,advanced gastric or gastroesophageal junction cancer who have previously received at least two lines of chemotherapy. | Zhi Peng Tianshu Liu Jia Wei Airong Wang Yifu He Liuzhong Yang Xizhi Zhang Nanfeng Fan Suxia Luo Zhen Li Kangsheng Gu Jianwei Lu Jianming Xu Qingxia Fan Ruihua Xu Liangming Zhang Enxiao Li Yuping Sun Guohua Yu Chunmei Bai Yong Liu Jiangzheng Zeng Jieer Ying Xinjun Liang Nong Xu Chao Gao Yongqian Shu Dong Ma Guanghai Dai Shengmian Li Ting Deng Yuehong Cui Jianmin Fang Yi Ba Lin Shen | 2021 | Cancer Communications2021，41，11： | 29 |
| 9 | Fibrinogen-like protein 2 fibroleukin expression and its correlation with disease progression in murine hepatitis virus type 3-induced fulminant hepatitis and in patients with severe viral hepatitis B显示文摘AIM: To evaluate the expression of fibrinogenlike protein 2 (fgl2) and its correlation with disease progression in both mice and patients with severe viral hepatitis.METHODS: Balb/cJ or A/J mice were infected intraperitoneally (ip) with 100 PFU of murine hepatitis virus type 3 (MHV-3), liver and serum were harvested at 24, 48, and 72 h post infection for further use. Liver tissues were obtained from 23 patients with severe acute chronic (AOC) hepatitis B and 13 patients with mild chronic hepatitis B. Fourteen patients with mild chronic hepatitis B with cirrhosis and 4 liver donors served as normal controls. In addition, peripheral blood mononuclear cells (PBMC) were isolated from 30 patients (unpaired) with severe AOC hepatitis B and 10 healthy volunteers as controls. Procoagulant activity representing functional prothrombinaseactivity in PBMC and white blood cells was also assayed. A polyclonal antibody against fgl2 was used to detect the expression of both mouse and human fgl2 protein in liver samples as well as in PBMC by immunohistochemistry staining in a separate set of studies. Alanine aminotransferase (ALT) and total bilirubin (TBil) in serum were measured to assess the severity of liver injury.RESULTS: Histological changes were found in liver sections 12-24 h post MHV-3 infection in Balb/cJ mice.In association with changes in liver histology, marked elevations in serum ALT and TBil were observed. Mouse fgl2 (mfgl2) protein was detected in the endothelium of intrahepatic veins and hepatic sinusoids within the liver 24 h after MHV-3 infection. Liver tissues from the patients with severe AOC hepatitis B had classical pathological features of acute necroinflammation. Human fgl2 (hfgl2)was detected in 21 of 23 patients (91.30%)with severe AOC hepatitis B, while only 1 of 13 patients(7.69%) with mild chronic hepatitis B and cirrhosis had hfgl2 mRNA or protein expression. Twenty-eight of thirty patients (93.33%) with severe AOC hepatitis B and 1of 10 with mild chronic hepatitis B had detectable hfgl2expression in PBMC. No hfgl2 expression was found either in the liver tissue or in the PBMC from normal donors. There was a positive correlation between hfgl2expression and the severity of the liver disease as indicated by the levels of TBil. PCA significantly increased in PBMC in patients with severe AOC hepatitis B.CONCLUSION: The molecular and cellular results reported here in both mice and patients with severe viral hepatitis suggest that virus-induced hfgl2prothrombinase/fibroleukin expression and the coagulation activity associated with the encoded fgl2protein play a pivotal role in initiating severe hepatitis.The measurement of hfgl2/fibroleukin expression in PBMC may serve as a useful marker to monitor the severity of AOC hepatitis B and a target for therapeutic intervention. | Chuan-Long Zhu Wei-Ming Yan Fan Zhu Yong-Fen Zhu Dong Xi De-Ying Tian Gary Levy Xiao-Ping Luo Qin Ning | 2005 | World Journal of Gastroenterology2005，11，44： | 26 |
| 10 | Decreased expression of serotonin in the jejunum and increased numbers of mast cells in the terminal ileum in patients with irritable bowel syndrome显示文摘AIM: To investigate if there are changes in serotonin (5-HT) levels, enterochromaffin (EC) cells and mast cells in small intestinal mucosa of patients with irritable bowel syndrome (IBS). METHODS: Diarrhea-predominant (IBS-D, n = 20), or constipation-predominant (IBS-C, n = 18) IBS patients and healthy controls (n = 20) underwent colonoscopy and peroral small intestinal endoscopy, and mucosal samples were obtained at the descending part of the duodenum, proximal end of jejunum and terminal ileum. High-performance liquid chromatography- electrochemistry and immunohistochemical methods were used to detect 5-HT content, EC cells and mast cells. RESULTS: (1) There were no differences in the number and distribution of EC cells between IBS patients and the normal group. (2) The mucosal 5-HT contents at the duodenum, jejunum and ileum in IBS-C patients were 182 ± 90, 122 ± 54, 61 ± 35 ng/mg protein, respectively, which were all lower than those in the normal group (256 ± 84, 188 ± 91, and 93 ± 45 ng/ mg protein, respectively), with a significant difference at the jejunum (P < 0.05). There were no differences in the small intestinal mucosal 5-HT contents between IBS-D patients and the normal group. The mucosal 5-HT contents at the duodenum were significantly higher than those at the ileum in the three groups (P < 0.001). (3) The numbers of mast cells in patients with IBS-C and IBS-D at the ileum were 38.7 ± 9.4 and 35.8 ± 5.5/highpower field (hpf), respectively, which were significantly more than that in the normal group (29.8 ± 4.4/hpf) (P < 0.001). There was no significant difference in the numbers of mast cells at the other two parts between IBS patients and the normal group. The numbers of mast cells in IBS-C, IBS-D, and normal groups were all significantly higher at the ileum (38.7 ± 9.4, 35.8 ± 5.5, 29.8 ± 4.4/hpf, respectively) than at the duodenum (19.6 ± 4.7, 18.5 ± 6.3, 19.2 ± 3.3/hpf, respectively, P < 0.001). CONCLUSION: The changes in the 5-HT signaling pathway at the jejunum of IBS-C patients and the increase in mast cells in patients with IBS at the terminal ileum may offer evidence to explain the pathogenesis of IBS. | Shen-Hao Wang Lei Dong Jin-Yan Luo Jun Gong Lu Li Xiao-Lan Lu Shui-Ping Han | 2007 | World Journal of Gastroenterology2007，13，45： | 25 |
| 11 | Blockchain: a secure, decentralized, trusted cyber infrastructure solution for future energy systems显示文摘Modern power systems are rapidly evolving into complex cyber-physical systems. The increasingly complex interaction among different energy entities calls for a secure, efficient, and robust cyber infrastructure. As an emerging distributed computing technology, Blockchain provides a secure environment to support such interactions.This paper gives a prospective on using Blockchain as a secure, distributed cyber infrastructure for the future grid.Firstly, the basic principles of Blockchain and its state-ofthe-art are introduced. Then, a Blockchain based smart grid cyber-physical infrastructure model is proposed. Afterwards, some promising application domains of Blockchain in future grids are presented. Following this, some potential challenges are discussed. | Zhaoyang DONG Fengji LUO Gaoqi LIANG | 2018 | Journal of Modern Power Systems and Clean Energy2018，6，5： | 24 |
| 12 | Reconstruction of temperature series of China for the last 1000 years显示文摘This paper reports a study on reconstructing temperature series for ten regions of China over the last 1000 years with a time resolution of 10 a. The regions concerned are: Northeast, North, East, South China, Taiwan, Central, Southwest, Northwest China, Xinjiang and Qinghai-Tibet Plateau. A variety of proxy data, such as ice core, tree-rings, stalagmites, peat, lake sediments, pollen and historical records, were validated with instrumental observations made in the last 120 years, and applied in the recon- struction of the temperature series. A temperature series for whole China is then established by aver- aging the ten regional series with a weighting proportional to the area of each region. Finally, tem- perature variations for the last 1000 years are examined, with special focus placed on the characteris- tics of the Medieval Warm Period (MWP), the Little Ice Age (LIA), and Modern Warming (MW). | WANG ShaoWu WEN XinYu LUO Yong DONG WenJie ZHAO ZongCi YANG Bao | 2007 | Chinese Science Bulletin2007，52，23： | 22 |
| 13 | Current status of diagnosis and treatment of bladder cancer in China-Analyses of Chinese Bladder Cancer Consortium database显示文摘Objective:To investigate current status of diagnosis and treatment of bladder cancer in China.Methods:A database was generated by Chinese Bladder Cancer Consortium(CBCC).From January 2007 to December 2012,14,260 cases from 44 CBCC centers were included.Data of diagnosis,treatment and pathology were collected.Results:The average age was 63.5 year-old and most patients were male(84.3%).The most common histologic types were urothelial carcinoma(91.4%),adenocarcinoma(1.8%),and squamous carcinoma(1.9%).According to 1973 and 2004 WHO grading system,42.0%,41.0%,and 17.0% of patients were grade 1,2,and 3,and 16.0%,48.7%,and 35.3% of patients were papillary urothelial neoplasms of low malignant potential,low,and high grade,respectively.Non-muscle invasive bladder cancer(NMIBC)and muscle invasive bladder cancer(MIBC)were 25.2% and 74.1%,respectively(0.8% not clear).Carcinoma in situ was only 2.4%.Most patients were diagnosed by white-light cystoscopy with biopsy(74.3%).Fluorescence and narrow band imaging cystoscopy had additional detection rate of 1.0% and 4.0%,respectively.Diagnostic transurethral resection(TUR)provided detection rate of 16.9%.Most NMIBCs were treated with TUR(89.2%).After initial TUR,2.6%accepted second TUR,and 45.7%,69.9%,and 58.7% accepted immediate,induced,and maintenance chemotherapy instillation,respectively.Most MIBCs were treated with radical cystectomy(RC,59.7%).Laparoscopic RCs were 35.1%,while open RC 63.4%.Extended and standard pelvic lymph node dissection were 7% and 66%,respectively.Three most common urinary diversions were orthotopic neobladder(44%),ileal conduit(31%),and ureterocutaneostomy(23%).Only 2.3% of patients accepted neo-adjuvant chemotherapy and only 18%of T3 and T4 patients accepted adjuvant chemotherapy.Conclusion:Disease characteristics are similar to international reports,while differences of diagnosis and treatment exist.This study can provide evidences for revisions of the guideline on bladder cancer in China. | Kaiwen Li Tianxin Lin 无 Wei Xue Xin Mu Enci Xu Xu Yang Fubao Chen Guangyong Li Lulin Ma Guoliang Wang Chaozhao Liang Haoqiang Shi Ming Li Mao Tang Xueyi Xue Yisong Lv Yaoliang Deng Chengyang Li Zhiwen Chen Xiaozhou Zhou Fengshuo Jin Xudong Liu Jinxin Wei Lei Shi Xin Gou Weiyang He Liqun Zhou Lin Cai Baiye Jin Guanghou Fu Xiangbo Kong Hongyan Sun Ye Tian Lang Feng Tiejun Pan Yiyi Wu Dongwen Wang Hailong Hao Benkang Shi Yaofeng Zhu Qiang Wei Ping Han Changli Wu Dawei Tian Zhangqun Ye Zheng Liu Zhiping Wang Junqiang Tian Lin Qi Minfeng Chen Wei Li Jinchun Qi Gongxian Wang Longlong Fu Zhaolin Sun Guangheng Luo Zhoujun Shen Zhaowei Zhu Jinchun Xing Zhun Wu Dong Wei Xin Chen Yanqun Na Hongfeng Guo Chunxi Wang Zhihua Lu Chuize Kong Yang Liu Jin Yang Jianyun Hu Xin Gao Jielin Li Changjun Yin Pu Li Shan Chen Zhen Du Jiongming Li Yongji Yan Xu Zhang Shuang Huang Fangjian Zhou Zhiling Zhang Yinghao Sun Shuxiong Zeng Song Cen Jiaquan Zhou Hanzhong Li Jin Wen Jian Huang | 2015 | Asian Journal of Urology2015，2，2： | 21 |
| 14 | Role of VEGF and CD44v6 in differentiating benign from malignant ascites显示文摘AIM: To detect the vascular endothelial growth factor (VEGF)and soluble splice variant 6 of CD44 (sCD44v6) levels in ascites and to explore their role in differentiating benign from malignant ascites.METHODS: Cirrhotic ascites (n=36), tuberculosis ascites (n=8) and malignant ascites (n=23) were collected and studied. Concentrations of soluble VEGF and sCD44v6 in various kinds of ascites (n=67) were measured using a sandwich enzyme-linked immunoadsorbent assay.RESULTS: VEGF and sCD44v6 levels in malignant ascites were 640.74±264.81 pg/ml and 89.22±38.20 ng/ml,respectively, both of which were significantly higher than those in cirrhotic ascites and tuberculous ascites (q=18.98,11.89 and q=8.92, 5.09; P<0.01). However, the levels of VEGF and sCD44v6 in cirrhotic and tuberculous ascites had no significant difference (q=0.48, 0.75; P>0.05).Furthermore, VEGF levels in malignant ascites in patients with ovarian cancer were higher than those with gastric and colon cancer (q=5.03, 6.79; P<0.01, respectively). But differences of VEGF levels between gastric and colon cancer were not significant (q=1.90, P>0.05). Whereas, sCD44v6 levels in malignant ascites from patients with ovadan, gastric and colon cancer had no significant difference (q=0.06, 0.91,0.35;P>0.05, respectirely). In comparison with cirrhotic and tuberculous ascites, when the upper limit of its VEGF mean levels 119.44 pg/ml (70.90±48.54) and sCD44v6 mean levels 63.59 ng/ml (44.42±19.17) was taken as the minimum cutoff limit, the sensitivity and specificity of VEGF and sCD44v6 of this assay to the diagnos is of malignant ascites were 91.3 %, 90.9 % and 73.9 %, 88.7 % respectively.CONCLUSION: Elevated levels of VEGF and sCD44v6 may be useful in differential diagnosis of benign and malignant ascites. | Wei-Guo Dong Xiao-Min Sun Bao-Ping Yu He-Sheng Luo Jie-Ping Yu, Department of Gastroenterology, Renmin Hospital, Wuhan University, Wuhan 430060, Hubei Province, China | 2003 | World Journal of Gastroenterology2003，9，11： | 21 |
| 15 | Fibrinogen-like protein 2/fibroleukin prothrombinase contributes to tumor hypercoagulability via IL-2 and IFN-γ显示文摘AIM: To examine the role of Fibrinogen-like protein 2 (fgl2)/fibroleukin in tumor development. Fgl2 has been reported to play a vital role in the pathogenesis in MHV-3 (mouse hepatitis virus) induced fulminant and severe hepatitis,spontaneous abortion,allo-and xeno-graft rejection by mediating 'immune coagulation'. METHODS: Tumor tissues from 133 patients with six types of distinct cancers and the animal tumor tissues from human hepatocellular carcinoma (HCC) model on nude mice (established from high metastasis HCC cell line MHCC97LM6) were obtained. RESULTS: Hfgl2 was detected in tumor tissues from 127 out of 133 patients as well as tumor tissues collected from human HCC nude mice. Hfgl2 was highly expressed both in cancer cells and interstitial inflammatory cells including macrophages,NK cells,and CD8+ T lymphocytes and vascular endothelial cells. Hfgl2 mRNA was localized in cells that expressed hfgl2 protein. Fibrin (nogen) co-localization with hfgl2 expression was determined by dual immunohistochemical staining. In vitro,IL-2 and IFN-γ increased hfgl2 mRNA by 10-100 folds and protein expression in both THP-1 and HUVEC cell lines. One-stage clotting assays demonstrated that THP-1 and HUVEC cells expressing hfgl2 had increased procoagulant activity following cytokines stimulation. CONCLUSION: The hfg12 contributes to the hypercoagulability in cancer and may induce tumor angiogenesis and metastasis via cytokine induction. | Kai Su Fang Chen Wei-Ming Yan Qi-Li Zeng Li Xu Dong Xi Bin Pi Xiao-Ping Luo Qin Ning | 2008 | World Journal of Gastroenterology2008，14，39： | 20 |
| 16 | Distribution of gamasid mites on small mammals in Yunnan Province, China显示文摘小哺乳动物的身体表面上的 gamasid 螨的调查从 1990 ~ 2004 在中国的云南省被执行。小哺乳动物主人是代表五个地理分区, HengduanMountains 的也就是中间的分区, Hengduan 山的南部的分区,云南的东方高原分区,云南的 WesternPlateau 分区和云南的南部的多山的分区的捕获的 from25 县。捕获了 10803 个小哺乳动物宿主在四目(Rodentia,食虫目, Scandentia 和兔类) 属于九个家庭, 29 个类和 52 种类。68 571 gamasid 螨的一个总数从捕获的小哺乳动物主人的身体表面被收集,所有 gamasid 螨被识别到 10 个家庭, 33 个类和 112 种类。这篇论文列出所有螨种,和他们的分类位置(类和家庭) 和他们的相应宿主。更多螨种类比在另外的地理分区在 Hengduan 山的 MiddleSubregion 被发现。在 Hengduan 山的中间的分区的螨和小哺乳动物的彻底的个人在五个地理分区也是最丰富的。三主导的螨种和三主导的小哺乳动物 hostsweredetermined 作为主导。在云南省的调查区域的种类。主导的主人是 Rattus flavipectus (它说明34.85%彻底的个人), Apodemuschevrieri (13.43%)和 Rattus norvegicus (10.40%)当时主导的 gamasid 螨种类 areLaelaps nuttalli ( Hirst , 1915 )(27.84%), Laelaps echidninus ( Berlese , 1887 )(18.38%)并且 Laelapsguizhouensis ( Gu et 王, 1981 )(14.79%)。结果在不同分区在云南省和不平的分发特征显示出 gamasidmites 的高种类差异。 | LI-PU LUO XIAN-GUO GUO TI-JUN QIAN DIAN WU XING-YUANMEN WEN-GE DONG | 2007 | Insect Science2007，14，1： | 20 |
| 17 | Clinical features and treatment status of hemifacial spasm in China显示文摘 | Wang Lin Hu Xingyue Dong Hongjuan Wang Wenzhao Huang Yue Jin Lingjing Luo Yumin Zhang Weixi Lian Yajun Liang Zhanhua Shang Huifang Feng Yabo wu Yiwen Chen Jun Luo Weifeng Wan Xinhua | 2014 | Chinese Medical Journal2014，，5： | 20 |
| 18 | Effect of resection following downstaging of unresectable hepatocelluar carcinoma by transcatheter arterial chemoembolization显示文摘背景这回顾的研究被承担在这 52 个病人,之中与在2004年1月和2008年12月 .Methods 之间的 unresectable hepatocellular 癌( HCC )在 52 个病人分析肝的切除术的结果肿瘤的吝啬的直径是 7.9 厘米( 4.4-15.5 厘米,中部 8.5 厘米)在第一 transcatheter 以前动脉的 chemoembolization (不作声) .After 1-6 时间不作声(中部 2 ),中部的肿瘤直径在 resection.The 持续时间 betw 以前被归结为 4.2 厘米( 0-8.4 厘米) | Shi Xian-jie Jin Xin Wang Mao-qiang Wei Li-xin Ye Hui-yi Liang Yu-rong Luo Ying Dong Jia-hong | 2012 | Chinese Medical Journal2012，，2： | 19 |
| 19 | Baicalin attenuates high fat diet-induced insulin resistance and ectopic fat storage in skeletal muscle,through modulating the protein kinase B/Glycogen synthase kinase 3 beta pathway显示文摘Insulin resistance is the pathophysiological basis of many diseases.Overcoming early insulin resistance highly significant in prevention diabetes,non-alcoholic fatty liver,and atherosclerosis.The present study aimed at evaluating the therapeutic effects of baicalin on insulin resistance and skeletal muscle ectopic fat storage in high fat diet-induced mice,and exploring the potential molecular mechanisms.Insulin resistance in mice was induced with a high fat diet for 16 weeks.Animals were then treated with three different doses of baicalin(100,200,and 400 mg·kg^(-1)·d^(-1)for 14 weeks.Fasting blood glucose,fasting serum insulin,glucose tolerance test(GTT),insulin tolerance test(ITT),and skeletal muscle lipid deposition were measured.Additionally,the AMP-activated protein kinase/acetyl-CoA carboxylase and protein kinase B/Glycogen synthase kinase 3 beta pathways in skeletal muscle were further evaluated.Baicalin significantly reduced the levels of fasting blood glucose and fasting serum insulin and attenuated high fat diet induced glucose tolerance and insulin tolerance.Moreover,insulin resistance was significantly reversed.Pathological analysis revealed baicalin dose-dependently decreased the degree of the ectopic fat storage in skeletal muscle.The properties of baicalin were mediated,at least in part,by inhibition of the AMPK/ACC pathway,a key regulator of de novo lipogenesis and activation of the Akt/GSK-3β pathway,a key regulator of Glycogen synthesis.These data suggest that baicalin,at dose up to 400 mg·kg^(-1)·d^(-1),is safe and able to attenuate insulin resistance and skeletal muscle ectopic fat storage,through modulating the skeletal muscle AMPK/ACC pathway and Akt/GSK-3β pathway. | XI You-Li LI Hong-Xia CHEN Chen LIU Ya-Qun LV Hong-Mei DONG Shi-Qi LUO Er-Fei GU Ming-Bo LIU Hua | 2016 | Chinese Journal of Natural Medicines2016，14，1： | 19 |
| 20 | Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma显示文摘AIM:To analyze prognostic factors for survival after transarterial chemoembolization(TACE)combined with microwave ablation(MWA)for hepatocellular carcinoma(HCC).METHODS:Clinical data of 86 patients who underwent TACE combined with MWA between January 2006and December 2013 were retrospectively analyzed in this study.Survival curves were detected using log-rank test.Univariate analysis was performed using log-rank test with respect to 13 prognostic factors affecting survival.All statistically significant prognostic factors identified by univariate analysis were entered into a Cox proportion hazards regression model to identify independent predictors of survival.P values were two-sided and P<0.05 was considered statistically significant.RESULTS:Median follow-up time was 47.6 mo,andmedian survival time of enrolled patients was 21.5 mo.The 1-,2-,3-and 5-year overall survival rates were72.1%,44.1%,31.4%and 13.9%,respectively.Tumor size(χ2=14.999,P=0.000),Barcelona Clinic Liver Cancer(BCLC)stage(χ2=29.765,P=0.000),ChildPugh class(χ2=51.820,P=0.000),portal vein tumor thrombus(PVTT)(χ2=43.086,P=0.000),arteriovenous fistula(χ2=29.791,P=0.000),MWA therapy times(χ2=12.920,P=0.002),Eastern Cooperative Oncology Group(ECOG)score(χ2=28.660,P=0.000)and targeted drug usage(χ2=10.901,P=0.001)were found to be significantly associated with overall survival by univariate analysis.Multivariate analysis identified that tumor size(95%CI:1.608-4.962,P=0.000),BCLC stage(95%CI:1.016-2.208,P=0.020),PVTT(95%CI:2.062-9.068,P=0.000),MWA therapy times(95%CI:0.402-0.745,P=0.000),ECOG score(95%CI:1.012-3.053,P=0.045)and targeted drug usage(95%CI:1.335-3.143,P=0.001)were independent prognostic factors associated with overall survival.CONCLUSION:Superior performance status,MWA treatment and targeted drug were favorable factors,and large HCC,PVTT and advanced BCLC stage were risk factors for survival after TACE-MWA for HCC. | Jia-Yan Ni Hong-Liang Sun Yao-Ting Chen Jiang-Hong Luo Dong Chen Xiong-Ying Jiang Lin-Feng Xu | 2014 | World Journal of Gastroenterology2014，20，46： | 18 |
您所在的机构暂未开通此部分的功能，请联系管理员